CG From the
-
Cell & Gene: The Podcast Covers CGT Companies in the News
2/23/2023
Sangamo Therapeutics, Mustang Bio, Cartesian Therapeutics and more have been in the news recently. Here's an update on what they've released as well as the Cell & Gene: The Podcast episodes that provide the important details that led to their the announcements.
-
Modernizing Efficient Payment Structures For CGTs
2/22/2023
Can the various stakeholders in the CGT sector modernize efficient payment structures quickly enough to keep pace with the science? The questions are complicated, the options are complicated, and so, too, are the potential solutions.
-
CGT’s Top Regulatory Challenges Broken Down By Segment
1/31/2023
Our recent Cell & Gene Live, Tackling Cell & Gene Therapies’ Top 3 Regulatory Impediments, featuring BridgeBio's Dr. Adora Ndu and REGENXBIO's Dr. Nina Hunter, delivered just under 60 minutes of exceptionally valuable information. We also know that your time is likely not your own, which is why we’ve broken down the full-length version into digestible segments that you can view on your own time.
-
XyloCor’s Phase 2 EXACT Trial Success
1/31/2023
XyloCor Therapeutics’ CEO, Albert Gianchetti provides updates about the clinical-stage biopharma’s EXACT clinical trial.
-
Astellas Pharma: Moving On from Clinical Hold
1/26/2023
Ha Tran, Executive Medical Director at Astellas Pharma, explains the cause of the clinical hold and the future of the program now that the hold has been lifted.
-
Atara Biotherapeutics, Kite, and Tmunity
1/17/2023
Inside the recent news out of Atara Biotherapeutics' allo approval and Kite's acquisition of Tmunity Therapeutics.
-
Tackling CGT’s Top 3 Regulatory Impediments
12/29/2022
2022 brought a great deal of change and disruption to cell and gene therapy companies. The news of companies closing their pipelines, undergoing liquidations, etc. was loud this year. The reasons for these pitfalls are varied and sundry, but despite the noise, cell and gene therapies have made impressive clinical progress. But the sector continues to face big hurdles, and overcoming regulatory challenges is one of them.
-
My Top Editorial Picks for 2022
12/19/2022
Fair warning, Cell & Gene readers. While this list includes some of my favorite editorial from 2022, it’s not even remotely close to being as extensive as I’d like. Why is that? Our library of content is so deep and so rich, I couldn’t possibly share and recap all of it with you in one article. Here are some highlights that helped to inform our readers about everything from process development to vendor selection to partnering with the right investment team.
-
How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing (Part 2)
12/9/2022
In the final part of the series, experts from Kite Pharma, Novartis Gene Therapies, and SwanBio explain how to drive down COGS and expedite commercial-scale manufacturing in the CGT space.
-
How To Reduce COGS & Expedite Commercial-Scale CGT Manufacturing (Part 1)
12/8/2022
In part one of this two-part series, as seen in Life Science Leader magazine, experts from Kite Pharma, Novartis Gene Therapies, and SwanBio weigh in on the understanding of how to drive down COGS and expedite commercial-scale manufacturing in the CGT space.